ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
Clinical trial NCT04143607 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04143607
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-23
- Primary completion
- 2024-03-31
- Enrollment
- 337
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.